Creo Medical Group PLC – Video featuring ‘Speedboat’ device

Creo Medical Group PLC – Video featuring ‘Speedboat’ device

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the Company’s Speedboat device has featured in a newly published video abstract entitled, “A new approach to endoscopic submucosal tunneling dissection: the “Speedboat-RS2″ device”. 

The video abstract has been published via an open access content publisher, Thieme Group. It is available in the Endoscopy E-videos section and can be viewed online here:

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0875-3352

The video abstract was authored by UK experts in the field of Gastrointestinal (“GI”) therapeutic endoscopy and users of Creo’s Speedboat device for colorectal endoscopic submucosal dissection, an advanced surgical procedure using endoscopy to remove gastrointestinal pre-cancerous lesions that have not entered the muscle layer. 

The authors were:

–      Dr Zacharias Tsiamoulos, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

–      Dr Joseph Sebastian, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

–      Dr Nipin Bagla, Consultant Histopathologist at Queen Elizabeth the Queen Mother Hospital, East Kent

–      Professor Brian Saunders, Consultant Gastroenterologist at St. Mark’s Hospital Foundation

–      Dr Chris Hancock, Founder and Chief Technology Officer, Creo Medical Group plc 

Craig Gulliford, Chief Executive Officer of Creo, commented:

“It is encouraging to see that additional case-studies of the effective clinical use of our Speedboat Device are being shared more and more widely amongst the Gastroenterological community. This video abstract provides another example of how our Speedboat technology provides precise dissection and controlled haemostasis using a single device. The technology will offer physicians a less invasive endoscopic surgical solution for removing pre-cancerous lesions in the colon, and one which significantly reduces procedure and recovery time as well as generating effective patient outcomes.”

No Comments

Post a Comment